MAP2K4 and leiomyosarcoma: PLX8725, a novel MAP2K4 inhibitor, demonstrates promising in vivo activity against patient-derived xenografts of uterine leiomyosarcomas harboring gain-of-function alterations in the MAP2K4 gene [66].